Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Summary

Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.

Timeline

Start

2021-12-06

Primary completion

2023-05-31

Completion

2023-05-31

Outcome

Outcome not reported

Stopped (Business): “Freeline has decided to pause development of FLT180a for business priorities”

Drugs

Indications